wegovy novo nordisk - Search News

News

Novo Nordisk, Wegovy

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly ,

Al Jazeera on MSN · 2d

Wegovy maker Novo Nordisk warns of layoffs as competition grows

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be unavoidable as competition heats up against its blockbuster obesity drug Wegovy amid rising pressure from rival Eli Lilly.

The Wall Street Journal on MSN · 2d

Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.

Lilly, Novo Nordisk and obesity

Fast Company · 1d

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

The Financial Times · 11h

Eli Lilly obesity pill disappoints and gives boost to arch-rival Novo Nordisk

Shares in US-based Lilly fell 14.2 per cent on the trial results, while stock in Danish arch-rival Novo Nordisk, the maker of the pioneering Ozempic weight-loss drug, rose 6.7 per cent. Novo Nordisk has been losing share to Lilly in the US in injectable weight-loss drugs.

Reuters · 1d

Lilly's obesity pill lags Novo's Wegovy injection in key trial

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy.

Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

Novo Nordisk: The Market Has Lost Its Mind

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

1don MSN

Why Novo Nordisk Stock Slipped Today

Novo Nordisk ( NVO 7.47%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

1don MSN

Wegovy, Mounjaro Sales in India Double on Month in July

Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data ...

Stocktwits on MSN3d

Novo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny Side

NYSE-listed shares of Danish drugmaker Novo Nordisk (NVO) fell about 3% on Tuesday morning after brokerage UBS downgraded the ...

3don MSN

Why Novo Nordisk Stock Is Down Again Today

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

4don MSN

Noom launches microdose copies of Novo's Wegovy at $119

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results